Analyst Ami Fadia from Needham maintained a Buy rating on Revolution Medicines (RVMD – Research Report) and keeping the price target at $59.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ami Fadia’s rating is based on the promising initial clinical data for Revolution Medicines’ zoldonrasib, a RAS(ON) G12D-selective inhibitor, in patients with non-small cell lung cancer (NSCLC). The Phase 1 study results showed a notable objective response rate (ORR) of 61% at a 1200 mg daily dosage, which is a significant improvement compared to previous data in pancreatic cancer patients.
The safety profile of zoldonrasib was consistent with earlier reports, although there were minor increases in Grade 3 treatment-related adverse events and dose interruptions. Despite these concerns, the higher clinical activity in G12D patients compared to other treatments, such as daraxonrasib, supports continued development of zoldonrasib both as a standalone therapy and in combination. This positive development, although in early stages and within a relatively small market, underpins the Buy rating for RVMD.
In another report released today, Barclays also maintained a Buy rating on the stock with a $72.00 price target.